Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects

Kannan Gunasekaran(Amgen (United States)), Martin Pentony, Min Shen, Logan Garrett, Carla Forte, Anne Woodward, Soo Bin Ng(Inflammation Research Foundation), Teresa L. Born(Inflammation Research Foundation), Marc W. Retter(Amgen (United States)), Kathy Manchulenko(Amgen (United States)), Heather Sweet(Amgen (United States)), Ian N. Foltz(Amgen (United States)), Michael Wittekind, Wei Yan
Journal of Biological Chemistry
April 17, 2010
Cited by 284Open Access
Full Text

Abstract

Naturally occurring IgG antibodies are bivalent and monospecific. Bispecific antibodies having binding specificities for two different antigens can be produced using recombinant technologies and are projected to have broad clinical applications. However, co-expression of multiple light and heavy chains often leads to contaminants and pose purification challenges. In this work, we have modified the CH3 domain interface of the antibody Fc region with selected mutations so that the engineered Fc proteins preferentially form heterodimers. These novel mutations create altered charge polarity across the Fc dimer interface such that coexpression of electrostatically matched Fc chains support favorable attractive interactions thereby promoting desired Fc heterodimer formation, whereas unfavorable repulsive charge interactions suppress unwanted Fc homodimer formation. This new Fc heterodimer format was used to produce bispecific single chain antibody fusions and monovalent IgGs with minimal homodimer contaminants. The strategy proposed here demonstrates the feasibility of robust production of novel Fc-based heterodimeric molecules and hence broadens the scope of bispecific molecules for therapeutic applications.


Related Papers

No related papers found

Powered by citation graph analysis